
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
On an ongoing basis, our office receives denials from managed care plans stating that repair codes are bundled or "incidental to" the excision codes.